Our Pricing

Wegovy Timeline: All Doses From 0.25mg to 2.4mg

Understanding the wegovy timeline doses uk schedule is essential for successful weight management outcomes. Wegovy (semaglutide) follows a carefully structured 16-20 week dose escalation protocol, starting at 0.25mg and gradually increasing to the 2.4mg maintenance dose. At Cured Pharmacy, our UK-registered prescribers guide you through each stage with transparent pricing from £79.00 and ongoing clinical support.

Wegovy Dose Escalation Schedule: The Complete Timeline

Wegovy's dosing schedule follows a medically supervised escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1]. The STEP clinical trial programme established this gradual titration approach, which typically spans 16-20 weeks before reaching the maintenance dose.

Each dose level serves a specific clinical purpose. The initial 0.25mg dose (weeks 1-4) allows your body to adapt to semaglutide's GLP-1 receptor activation. You then progress to 0.5mg (weeks 5-8), 1mg (weeks 9-12), and 1.7mg (weeks 13-16) before reaching the target 2.4mg maintenance dose from week 17 onwards [1]. This structured approach reduces the likelihood of nausea, vomiting, and treatment discontinuation compared to rapid dose increases.

Clinical data from the STEP 1 trial demonstrated that patients who completed the full dose escalation achieved an average 14.9% body weight reduction over 68 weeks, with the majority of weight loss occurring after reaching the 1.7mg and 2.4mg doses [2]. The gradual timeline ensures your body adapts to each increment whilst building sustainable eating behaviour changes.

What to Expect at Each Wegovy Dose Level

During the 0.25mg starting dose (month 1), most patients experience minimal side effects as their body begins adapting to GLP-1 receptor agonism. You may notice slight appetite reduction, though significant weight loss typically doesn't occur at this introductory level. This dose establishes treatment tolerance and allows our UK prescribers to monitor your initial response.

The 0.5mg dose (month 2) often marks the first noticeable appetite suppression for many patients. Mild nausea affects approximately 20-30% of users at this stage, though symptoms typically resolve within 2-3 weeks as your body adjusts [3]. Average weight loss during this phase ranges from 2-4% of baseline body weight in clinical trials.

At 1mg (month 3), appetite control becomes more pronounced, and weight loss typically accelerates. This dose represents a therapeutic threshold where many patients report significant changes in food cravings and portion sizes. The 1.7mg dose (month 4) further enhances these effects, with clinical data showing continued weight reduction averaging 8-10% of baseline weight by this stage [2].

The 2.4mg maintenance dose delivers Wegovy's full therapeutic effect. In the STEP trials, patients who reached and maintained this dose achieved the highest weight loss outcomes, with effects plateauing around 60-68 weeks of continuous treatment [2]. Subject to prescriber approval, you'll remain on this dose long-term to sustain weight management results.

Managing Side Effects Throughout the Timeline

Gastrointestinal side effects peak during dose escalation periods, typically within 2-3 days of each increase and subsiding over the following 1-2 weeks. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce nausea severity. If side effects become unmanageable, your UK prescriber may extend the duration at your current dose before progressing to the next level.

Staying well-hydrated throughout the Wegovy timeline is critical, particularly during the first 12 weeks when nausea and reduced fluid intake can lead to dehydration. Our clinical team at Cured Pharmacy monitors your progress through regular check-ins, adjusting your timeline if necessary to ensure both safety and treatment adherence.

How Long Does Each Wegovy Dose Last?

The standard Wegovy timeline allocates four weeks at each dose level: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg from week 17 onwards [1]. This 16-week escalation period represents the minimum duration recommended by the MHRA-approved prescribing information.

However, individual timelines may vary based on tolerability and clinical response. Some patients require extended periods at intermediate doses—particularly at 1mg or 1.7mg—if they experience persistent side effects. Conversely, patients with excellent tolerance may progress slightly faster under prescriber supervision, though accelerated escalation isn't routinely recommended due to increased gastrointestinal adverse event rates [3].

Once you reach the 2.4mg maintenance dose, you continue this weekly injection indefinitely as long as treatment remains clinically appropriate and effective. The STEP 4 trial examined treatment discontinuation, finding that patients who stopped Wegovy regained approximately two-thirds of their lost weight within 52 weeks, underscoring the importance of long-term maintenance therapy [4].

Adjusting Your Timeline: When Flexibility Is Needed

UK prescribers may modify the standard Wegovy timeline based on individual circumstances. If you experience severe nausea, vomiting, or other dose-limiting side effects, your prescriber might pause escalation and maintain your current dose for an additional 2-4 weeks. This flexible approach prioritises treatment adherence over rigid protocol adherence.

Patients who achieve significant weight loss at intermediate doses (such as 1mg or 1.7mg) may occasionally remain at that level rather than progressing to 2.4mg, particularly if they've reached their target weight or experience diminishing returns. These decisions require ongoing consultation with your UK prescriber and aren't made unilaterally.

Wegovy Timeline vs Other Weight Loss Treatments

Compared to alternative weight loss medications available through UK pharmacies, Wegovy's 16-week dose escalation represents a moderate timeline. Saxenda (liraglutide) requires daily injections with a faster 5-week escalation to its 3mg maintenance dose, whilst Mounjaro (tirzepatide) follows a similar monthly escalation pattern over 16-20 weeks to reach its 15mg maximum dose.

The gradual Wegovy timeline offers distinct advantages for treatment adherence. Clinical data suggests that slower titration schedules correlate with lower discontinuation rates, as patients have adequate time to adapt both physiologically and behaviourally to appetite changes [3]. This structured approach also allows UK prescribers to identify and address potential complications early, before they become treatment-limiting.

From a practical standpoint, the weekly injection frequency throughout the entire Wegovy timeline provides convenience compared to daily injection regimens. Each pre-filled pen delivers a single dose, eliminating dosing errors and simplifying the treatment routine for busy patients managing work, family, and health commitments.

Weight Loss Expectations Throughout the Wegovy Timeline

Weight loss patterns during the Wegovy timeline follow a predictable trajectory in most patients. Minimal weight change occurs during the first 4-8 weeks at 0.25mg and 0.5mg doses, as these levels primarily establish treatment tolerance rather than deliver full therapeutic effect. Noticeable weight reduction typically begins around weeks 8-12 as you reach the 1mg dose [2].

The most significant weight loss occurs between weeks 12-40, spanning the 1mg, 1.7mg, and initial 2.4mg maintenance period. STEP trial data showed that average weekly weight loss peaked at approximately 0.5-1kg during this phase, though individual results varied considerably based on baseline weight, dietary adherence, and physical activity levels [2].

Weight loss typically plateaus around 60-68 weeks of continuous treatment, with patients maintaining their reduced weight rather than experiencing ongoing reductions indefinitely [2]. This plateau represents a new metabolic equilibrium rather than treatment failure. Continuing the 2.4mg maintenance dose prevents weight regain, which occurs rapidly upon treatment discontinuation as demonstrated in the STEP 4 withdrawal study [4].

Realistic expectations are essential throughout the Wegovy timeline. Whilst clinical trials showed average weight reductions of 14.9% over 68 weeks, individual outcomes ranged from 5% to over 20% [2]. Your UK prescriber will help you set achievable targets based on your baseline BMI, medical history, and weight loss goals, adjusting expectations as you progress through each dose level.

Factors That Influence Your Timeline Results

Several variables affect weight loss outcomes throughout the Wegovy timeline. Baseline BMI significantly impacts results, with higher starting weights typically achieving greater absolute weight loss but similar percentage reductions. Adherence to weekly injections is critical—missing doses disrupts the steady-state semaglutide levels necessary for consistent appetite suppression.

Dietary quality and physical activity levels complement Wegovy's pharmacological effects. Patients who combine treatment with structured nutrition plans and regular exercise consistently achieve superior outcomes compared to those relying on medication alone. Our clinical team at Cured Pharmacy provides guidance on evidence-based lifestyle modifications that enhance your Wegovy timeline results whilst ensuring sustainable long-term weight management.

Starting Your Wegovy Timeline at Cured Pharmacy

Beginning Wegovy treatment through Cured Pharmacy involves a streamlined three-step process. First, complete our free online consultation, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications to GLP-1 therapy. Our UK-registered prescribers review your submission within 24 hours.

If Wegovy is clinically appropriate for you, your prescription is issued and your first 0.25mg dose is dispensed from our UK-registered pharmacy (GPhC 9012511). We provide comprehensive dosing instructions, side effect management guidance, and a clear timeline showing when you'll progress to each subsequent dose level. All medications arrive in 100% discreet packaging with next-day delivery options available.

Throughout your Wegovy timeline, you'll have ongoing access to our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We monitor your progress, address any concerns, and coordinate dose escalations according to your individual response and tolerability. Transparent pricing from £79.00 means you'll know your costs upfront, with no hidden fees or surprise charges as you progress through the treatment schedule.

All Wegovy supplies at Cured Pharmacy are genuine UK-licensed medications sourced directly from authorised wholesalers. We never dispense unlicensed imports or compounded alternatives. Your safety and treatment efficacy are our primary concerns throughout your entire Wegovy timeline, from the initial 0.25mg dose through long-term 2.4mg maintenance therapy.

Ongoing Support Throughout Your Treatment

Unlike one-off prescription services, Cured Pharmacy provides continuity of care throughout your entire Wegovy timeline. As you transition between dose levels, our prescribers review your progress, adjust timing if needed, and ensure you're achieving expected outcomes. This ongoing relationship optimises both safety and effectiveness, addressing potential issues before they compromise your treatment journey.

You can contact our team at (+44) 116 4646009 during business hours for any timeline-related questions or concerns. Whether you're experiencing unexpected side effects, unsure about dose escalation timing, or simply want reassurance about your progress, our UK-registered pharmacists and prescribers are available to provide expert guidance tailored to your individual circumstances.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) 2.4mg Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA). https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including baseline weight, adherence to treatment, dietary modifications, and physical activity levels. Wegovy is a prescription-only medicine in the UK and must be prescribed by a qualified healthcare professional following appropriate clinical assessment.